arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2025-2583AXVZSAarthyper-2583Research ArticleСтатьиArticlesФиксированные и свободные комбинации антигипертензивных препаратов: приверженность к лечению и влияние на сердечно-сосудистые исходы. Обзор литературыFixed and free combinations of antihypertensive drugs: adherence to treatment and impact on cardiovascular outcomes. Literature reviewhttps://orcid.org/0000-0002-1068-1650ГауэртВ. Р.GauertV. R.

Гауэрт Вероника Рудольфовна - кандидат медицинских наук, доцент кафедры эндокринологии,

ул. Революционная, д. 5, Ярославль, 150000

Veronika R. Gauert - MD, PhD, Associate Professor, Department of Endocrinology,

5 Revolutsionnaya str., Yaroslavl, 150000 

gauert68@mail.ruФедеральное государственное бюджетное образовательное учреждение высшего образования «Ярославский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияYaroslavl State Medical UniversityRussian Federation202502032026316598607Copyright © Гауэрт В.Р., 20262026Гауэрт В.Р.Gauert V.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/2583

Артериальная гипертензия (АГ) остается ведущим фактором риска сердечно-сосудистых (СС) заболеваний и преждевременной смертности во всем мире. Для достижения целевых уровней артериального давления (АД) большинству пациентов требуется комбинированная терапия. Современные российские и зарубежные клинические рекомендации поддерживают преимущественное использование фиксированных комбинаций (ФК) при терапии пациентов с АГ. Проводятся сравнительные исследования, посвященные вопросу - ФК превосходят или, напротив, уступают свободным комбинациям (СК) по эффективности и безопасности. В настоящей статье рассмотрены вопросы, касающиеся сравнения ФК и СК антигипертензивных препаратов в отношении эффективности контроля АД, приверженности терапии и влияния на риски СС осложнений и смертность. Продемонстрированы исследования, показывающие, что ФК являются эффективной стратегией контроля АД и снижения СС риска, особенно у пациентов с низкой приверженностью к лечению. Однако терапия СК остается предпочтительной при необходимости персонализированной медикаментозной терапии АГ. Следовательно, рациональный выбор антигипертензивной терапии требует учета конкретной клинической ситуации и индивидуальных факторов риска.

Arterial hypertension (HTN) remains the leading risk factor for cardiovascular diseases and premature mortality worldwide. To achieve the target blood pressure (BP) levels, most patients require combination therapy. Current Russian and international clinical guidelines support the preferential use of fixed combinations (FC) in the treatment of patients with HTN. Comparative studies aim to solve the question whether FC is superior or inferior to free (separate) combinations (SC) in terms of effectiveness and safety. This article discusses issues related to the comparison of FC versus SC of antihypertensive drugs for the effective BP control, adherence to therapy, and the impact on the risks of cardiovascular complications and mortality. FC were shown to be an effective strategy for BP control and reducing cardiovascular risk, especially in patients with low adherence to treatment. However, SC therapy remains preferable when personalized treatment is needed. Therefore, the rational choice of antihypertensive therapy requires consideration of the specific clinical situation and individual risk factors.

артериальная гипертензияфиксированные комбинациисвободные комбинациисердечно-сосудистые рискиприверженность терапиисмертностьhypertensionfixed combinationsfree combinationscardiovascular risksadherence to therapymortalityСтатья подготовлена при поддержке компании «Сервье» (Франция).This article was funded by SERVIER (France).ReferencesБаланова Ю.А., Шальнова С.А., Имаева А.Э., Капустина А.В., Муромцева Г.А., Евстифеева С.Е. и др. Распространенность артериальной гипертонии, охват лечением и его эффективность в Российской Федерации (данные наблюдательного исследования ЭССЕ-РФ-2). Рациональная Фармакотерапия в Кардиологии. 2019;15(4):450–466. https://doi.org/10.20996/1819-6446-2019-15-4-450-466Balanova YuA, Shalnova SA, Imaeva AE, Kapustina AV, Muromtseva GA, Evstifeeva SE, et al. Prevalence of arterial hypertension, treatment coverage, and its effectiveness in the Russian Federation (data from the ESSE-RF-2 study). Rational Pharmacotherapy in Cardiology. 2019;15(4):450–466. (In Russ.) https://doi.org/10.20996/1819-6446-2019-15-4-450-466Jeemon P, Séverin T, Amodeo C, Adler AJ, Agodoa L, Agyemang C, et al. World heart federation roadmap for hypertension — a 2021 update. Glob Heart. 2021;16(1):63. https://doi.org/10.5334/gh.1066Jeemon P, Séverin T, Amodeo C, Adler AJ, Agodoa L, Agyemang C, et al. World heart federation roadmap for hypertension — a 2021 update. Glob Heart. 2021;16(1):63. https://doi.org/10.5334/gh.1066Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol. 2021;18(11):785–802. https://doi.org/10.1038/s41569-021-00559-8Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol. 2021;18(11):785–802. https://doi.org/10.1038/s41569-021-00559-8World Health Organization. Global report on hypertension: the race against a silent killer. Geneva: World Health Organization; 2023 Sep 19 [cited 2023 Sep 20]. 276 p. Available from: https://www.who.int/publications/i/item/9789240081062World Health Organization. Global report on hypertension: the race against a silent killer. Geneva: World Health Organization; 2023 Sep 19 [cited 2023 Sep 20]. 276 p. Available from: https://www.who.int/publications/i/item/9789240081062Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957–980. https://doi.org/10.1016/S0140-6736(21)01330-1Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957–980. https://doi.org/10.1016/S0140-6736(21)01330-1Баланова Ю.А., Драпкина О.М., Куценко В.А., Имаева А.Э., Концевая М.В., Максимов С.А. и др. Артериальная гипертония в российской популяции в период пандемии COVID-19: гендерные различия в распространенности, лечении и его эффективности. Данные исследования ЭССЕ-РФ3. Кардиоваскулярная терапия и профилактика. 2023;22(8S):3785. https://doi.org/10.15829/1728-8800-2023-3785Balanova YA, Drapkina OM, Kutsenko VA, Imaeva AE, Kontsevaya MV, Maksimov SA, et al. Arterial hypertension in the Russian population during the COVID-19 pandemic: gender differences in prevalence, treatment, and effectiveness. Data from the ESSE-RF3 study. Cardiovascular Therapy and Prevention. 2023;22(8S):3785. (In Russ.) https://doi.org/10.15829/1728-8800-2023-3785Баланова Ю.А., Шальнова С.А., Куценко В.А., Имаева А.Э., Капустина А.В., Муромцева Г.А. и др. Вклад артериальной гипертонии и других факторов риска в выживаемость и смертность в российской популяции. Кардиоваскулярная терапия и профилактика. 2021;20(5):3003. https://doi.org/10.15829/1728-8800-2021-3003Balanova YA, Shalnova SA, Kutsenko VA, Imaeva AE, Kapustina AV, Muromtseva GA, et al. The contribution of arterial hypertension and other risk factors to survival and mortality in the Russian population. Cardiovascular Therapy and Prevention. 2021;20(5):3003. (In Russ.) https://doi.org/10.15829/1728-8800-2021-3003The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575–1585. https://doi.org/10.1056/NEJMoa1001286The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575–1585. https://doi.org/10.1056/NEJMoa1001286The ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829–840. https://doi.org/10.1016/S0140-6736(07)61303-8The ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829–840. https://doi.org/10.1016/S0140- 6736(07)61303-8Баланова Ю. А., Шальнова С. А., Куценко В. А., Имаева А. Э., Капустина А.В., Муромцева Г. А. и др. Популяционные аспекты терапии артериальной гипертензии. Фокус на фиксированные комбинации. Артериальная гипертензия. 2022;28(5):482–491. https://doi.org/10.18705/1607-419X-2022-28-5-482-491Balanova YA, Shalnova SA, Kutsenko VA, Imaeva AE, Kapustina AV, Muromtseva GA, et al. Population aspects of hypertension therapy: focus on fixed combinations. Arterial’naya Gipertenziya = Arterial Hypertension. 2022;28(5):482–491. (In Russ.) https://doi.org/10.18705/1607-419X-2022-28-5-482-491Карпов Ю.А., Горбунов В.М., Логунова Н.А. Применение тройной фиксированной комбинации в лечении артериальной гипертензии — возможность эффективного контроля артериального давления при использовании комбинированной антигипертензивной терапии: основные результаты Российского наблюдательного исследования ТРИКОЛОР. Российский кардиологический журнал. 2020;25(10):4130. https://doi.org/10.15829/1560-4071-2020-4130Karpov YA, Gorbunov VM, Logunova NA. Use of triple fixed combination in hypertension treatment: possibility of effective blood pressure control with combined antihypertensive therapy. Main results of the Russian observational study TRICOLOR. Russian Journal of Cardiology. 2020;25(10):4130. (In Russ.) https://doi.org/10.15829/1560-4071-2020-4130Blood Pressure Lowering Treatment Trialists’ Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021;397(10285):1625–1636. https://doi.org/10.1016/S0140-6736(21)00590-0Blood Pressure Lowering Treatment Trialists’ Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analy sis. Lancet. 2021;397(10285):1625–1636. https://doi.org/10.1016/S0140-6736(21)00590-0Tóth K. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high-rISk hyperTensive patients). Am J Cardiovasc Drugs. 2014;14(2):137–145. https://doi.org/10.1007/s40256-014-0067-2Tóth K. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high-rISk hyperTensive patients). Am J Cardiovasc Drugs. 2014;14(2):137–145. https://doi.org/10.1007/s40256-014-0067-2Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104. https://doi.org/10.1093/eurheartj/ehy339Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104. https://doi.org/10.1093/eurheartj/ehy339Mazza A, Lenti S, Schiavon L, Sacco AP, Dell'Avvocata F, Rigatelli G, Ramazzina E. Fixed-dose triple combination of antihypertensive drugs improves blood pressure control: from clinical trials to clinical practice. Adv Ther. 2017;34(4):975–985 https://doi.org/10.1007/s12325-017-0511-1Mazza A, Lenti S, Schiavon L, Sacco AP, Dell'Avvocata F, Rigatelli G, Ramazzina E. Fixed-dose triple combination of antihypertensive drugs improves blood pressure control: from clinical trials to clinical practice. Adv Ther. 2017;34(4):975–985 https://doi.org/10.1007/s12325-017-0511-1Mallat SG, Tanios BY, Itani HS, Lotfi T, Akl EA. Free versus fixed combination antihypertensive therapy for essential arterial hypertension: a systematic review and meta-analysis. PLoS ONE. 2016;11(8): e0161285. https://doi.org/10.1371/journal.pone.0161285Mallat SG, Tanios BY, Itani HS, Lotfi T, Akl EA. Free versus fixed combination antihypertensive therapy for essential arterial hypertension: a systematic review and meta-analysis. PLoS ONE. 2016;11(8): e0161285. https://doi.org/10.1371/journal.pone.0161285Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713–719. https://doi.org/10.1016/j.amjmed.2006.08.033Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713–719. https://doi.org/10.1016/j.amjmed.2006.08.033Sherrill B, Halpern M, Khan S, Zhang J, Panjabi S. Singlepill vs free-equivalent combination therapies for hypertension: ametaanalysis of health care costs and adherence. J Clin Hypertens (Greenwich). 2011;13(12):898–909. https://doi.org/10.1111/j.1751-7176.2011.00550.xSherrill B, Halpern M, Khan S, Zhang J, Panjabi S. Singlepill vs free-equivalent combination therapies for hypertension: ametaanalysis of health care costs and adherence. J Clin Hypertens (Greenwich). 2011;13(12):898–909. https://doi.org/10.1111/j.1751-7176.2011.00550.xBorghi C, Balagopalan P, Konradi A, Bortolotto LA, Degli Esposti L, Perrone V, et al. Adherence to triple single-pill combination of perindopril/indapamide/amlodipine: findings from real-world analysis in Italy. Adv Ther. 2023;40(1):1765–1722. https://doi.org/10.1007/s12325-023-02451-yBorghi C, Balagopalan P, Konradi A, Bortolotto LA, Degli Esposti L, Perrone V, et al. Adherence to triple single-pill combination of perindopril/indapamide/amlodipine: findings from real-world analysis in Italy. Adv Ther. 2023;40(1):1765–1722. https://doi. org/10.1007/s12325-023-02451-yRea F, Morabito G, Savaré L, Pathak A, Corrao G, Mancia G. Adherence and related cardiovascular outcomes to single-pill vs separate-pill administration of antihypertensive triple-combination therapy. Journal of Hypertension. 2023;41(9):1758–1767. http://journals.lww.com/jhypertensionRea F, Morabito G, Savaré L, Pathak A, Corrao G, Mancia G. Adherence and related cardiovascular outcomes to single-pill vs separate-pill administration of antihypertensive triple-combination therapy. Journal of Hypertension. 2023;41(9):1758–1767. http://journals.lww.com/jhypertensionMorabito G, Rea F, Corrao G, Mancia G. Adherence to perindopril/amlodipine/atorvastatin combination according to the administration strategy: a real-world retrospective analysis. European Heart Journal – Quality of Care and Clinical Outcomes. 2025;qcae116. https://doi.org/10.1093/ehjqcco/qcae116Morabito G, Rea F, Corrao G, Mancia G. Adherence to perindopril/amlodipine/atorvastatin combination according to the administration strategy: a real-world retrospective analysis. European Heart Journal – Quality of Care and Clinical Outcomes. 2025;qcae116. https://doi.org/10.1093/ehjqcco/qcae116Wang N, Salam A, Webster R, de Silva A, Guggilla R, Stepien S, et al. Association of low-dose triple combination therapy with therapeutic inertia and prescribing patterns in hypertension: a secondary analysis of the TRIUMPH randomized clinical trial. JAMA Cardiol. 2020;5(11): 1219–1226. https://doi.org/10.1001/jamacardio.2020.2739Wang N, Salam A, Webster R, de Silva A, Guggilla R, Stepien S, et al. Association of low-dose triple combination therapy with therapeutic inertia and prescribing patterns in hypertension: a secondary analysis of the TRIUMPH randomized clinical trial. JAMA Cardiol. 2020;5(11): 1219–1226. https://doi.org/10.1001/jamacardio.2020.2739Збышевская Е.В., Гумерова В.Е., Эринчек В.П., Логунова Н.А. Оценка эффективности тройной фиксированной комбинации у пациентов с недостаточным контролем артериального давления. Российский кардиологический журнал. 2022;27(1):4821. https://doi.org/10.15829/1560-4071-2022-4821Zbyshevskaya EV, Gumerova VE, Erinchek VP, Logunova NA. Evaluation of the efficacy of triple fixed combination therapy in patients with insufficient blood pressure control. Russian Journal of Cardiology. 2022;27(1):4821. (In Russ.) https://doi.org/10.15829/1560-4071-2022-4821Кашталап В.В. Медикаментозная терапия артериальной гипертонии и дислипидемии: возможности препарата Липертанс (на примере клинического наблюдения). Российский кардиологический журнал. 2022;27(11):5285. https://doi.org/10.15829/1560-4071-2022-5285Kashtalap VV. Therapy for hypertension and dyslipidemia: potential of Lipertans (on the example of a clinical observation). Russian Journal of Cardiology. 2022;27(11):5285. (In Russ.) https://doi.org/10.15829/1560-4071-2022-5285Ежов М.В., Кухарчук В.В., Сергиенко И.В., Ахмеджанов Н.М., Воевода М.И., Гуревич В.С. и др. Существующие проблемы и новые возможности в лечении дислипидемий. Совместное заключение по итогам Экспертного совета. Рациональная фармакотерапия в кардиологии. 2021;17(1):169–172. https://doi.org/10.20996/1819-6446-2021-02-02Ezhov MV, Kukharchuk VV, Sergienko IV, Akhmedzhanov NM, Voevoda MI, Gurevich VS, et al. Existing problems and new opportunities in the treatment of dyslipidemia. Joint conclusion based on the results of the Expert Council. Rational Pharmacotherapy in Cardiology. 2021;17(1):169–172. (In Russ.) https://doi.org/10.20996/1819-6446-2021-02-02Wald DS, Wald NJ, Morris JK, Taylor DJ, Law M. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11 000 participants from 42 trials. Am J Med. 2009;122(3):290–300. https://doi.org/10.1016/j.amjmed.2008.09.038Wald DS, Wald NJ, Morris JK, Taylor DJ, Law M. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11 000 participants from 42 trials. Am J Med. 2009;122(3):290–300. https://doi.org/10.1016/j.amjmed.2008.09.038Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887–1898. https://doi.org/10.1056/NEJMoa0801369Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887–1898. https://doi.org/10.1056/NEJMoa0801369Ho CT, Tung YC, Chou SH, Hsiao FC, Lin YS, ChangCJ, et al. Clinical outcomes in hypertensive patients treated with a single-pill fixed-dose combination of renin-angiotensin system inhibitor and thiazide diuretic. J Clin Hypertens (Greenwich). 2018;20(12):1731– 1738. https://doi.org/10.1111/jch.13413Ho CT, Tung YC, Chou SH, Hsiao FC, Lin YS, ChangCJ, et al. Clinical outcomes in hypertensive patients treated with a single-pill fixed-dose combination of renin-angiotensin system inhibitor and thiazide diuretic. J Clin Hypertens (Greenwich). 2018;20(12):1731– 1738. https://doi.org/10.1111/jch.13413Weisser B, Wassmann S, Predel HG, Schmieder RE, Gillessen A, Wilke T, et al. Effect of a single pill concept on clinical and pharmacoeconomic outcomes in cardiovascular diseases. Eur Heart J Cardiovasc Pharmacother. 2025;10(8):686–693. https://doi.org/10.1093/ehjcvp/pvae059Weisser B, Wassmann S, Predel HG, Schmieder RE, Gillessen A, Wilke T, et al. Effect of a single pill concept on clinical and pharmacoeconomic outcomes in cardiovascular diseases. Eur Heart J Cardiovasc Pharmacother. 2025;10(8):686–693. https://doi.org/10.1093/ehjcvp/pvae059Snyman JR, Bortolotto LA, Degli Esposti L, Jayagopal PB, Konradi AO, Perrone V, et al. A real-world analysis of outcomes and healthcare costs of patients on perindopril/indapamide/amlodipine single-pill vs. multiple-pill combination in Italy. J Hypertens. 2024;42(1):136–142. https://doi.org/10.1097/HJH.0000000000003570Snyman JR, Bortolotto LA, Degli Esposti L, Jayagopal PB, Konradi AO, Perrone V, et al. A real-world analysis of outcomes and healthcare costs of patients on perindopril/indapamide/amlodipine single-pill vs. multiple-pill combination in Italy. J Hypertens. 2024;42(1):136–142. https://doi.org/10.1097/HJH.0000000000003570Котовская Ю.В. Пожилой пациент с артериальной гипертонией: фокус на индивидуализацию терапии. Терапия. 2022;8(9):145–151. https://doi.org/10.18565/therapy.2022.9.145-151Kotovskaya YV. Elderly patient with arterial hypertension: focus on therapy individualization. Therapy. 2022;8(9):145–151. https://doi.org/10.18565/therapy.2022.9.145-151Медведева Е.А., Усова Е.И., Соловьева А.Е., Дубинина М.В., Виллевальде С.В., Звартау Н.Э. и др. Пациенты с артериальной гипертензией и хронической болезнью почек как приоритетная группа для программ первичной профилактики. Российский кардиологический журнал. 2024;25(8):581–592. https://doi.org/10.15829/1560-4071-2024-5812Medvedeva EA, Usova EI, Solovyova AE, Dubinina MV, Villevalde SV, Zvartau NE, et al. Patients with hypertension and chronic kidney disease as a priority group for primary prevention programs. Russian Journal of Cardiology. 2024;29(3):5812. (In Russ.) https://doi.org/10.15829/1560-4071-2024-5812McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al; ESC Scientific Document Group. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912–4018. https://doi.org/10.1093/eurheartj/ehae178.McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al; ESC Scientific Document Group. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912–4018. https://doi.org/10.1093/eurheartj/ehae178.Moriarty F, Bennett K, Fahey T. Fixed-dose combination antihypertensives and risk of therapeutic duplication and drug interactions: a population-based cohort study. Heart. 2019;105(3):204–210. https://doi.org/10.1136/heartjnl-2018-313492Moriarty F, Bennett K, Fahey T. Fixed-dose combination antihypertensives and risk of therapeutic duplication and drug interactions: a population-based cohort study. Heart. 2019;105(3):204–210. https://doi.org/10.1136/heartjnl-2018-313492Левченкова О.С., Галимулина Р. Р., Комев Б. Р., Загнет К.Д. Выбор между фиксированными дозированными комбинациями антигипертензивных средств и их свободными комбинациями в лечении артериальной гипертензии. Архивъ внутренней медицины. 2024;14(5):325–338. https://doi.org/10.20514/2226-6704-2024-14-5-325-338Levchenkova OS, Galimulina RR, Komev BR, Zagnet KD. Choice between free combination of antihypertensive agents and fixed dosed combinations in the treatment of arterial hypertension. The Russian Archives of Internal Medicine. 2024;14(5):325–338. https://doi.org/10.20514/2226-6704-2024-14-5-325-338Magee LA, Abalos E, von Dadelszen P, Sibai B, Easterling T, Walkinshaw S, et al. How to manage hypertension in pregnancy effectively: a meta-analysis of randomized trials. Br J Clin Pharmacol. 2011;72(2):177–187. https://doi.org/10.1111/j.1365-2125.2011.04002.xMagee LA, Abalos E, von Dadelszen P, Sibai B, Easterling T, Walkinshaw S, et al. How to manage hypertension in pregnancy effectively: a meta-analysis of randomized trials. Br J Clin Pharmacol. 2011;72(2):177–187. https://doi.org/10.1111/j.1365-2125.2011.04002.xWilliams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomized, double-blind, crossover trial. Lancet. 2015;386(10008):2059–2068. https://doi.org/10.1016/S0140-6736(15)00257-3Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomized, double-blind, crossover trial. Lancet. 2015;386(10008):2059–2068. https://doi.org/10.1016/S0140-6736(15)00257-3Hutchinson B, Husain MJ, Nugent R, Kostova D. Comparing scale up of status quo hypertension care against dual combination therapy as separate pills or single pill combinations: an economic evaluation in 24 low- and middle-income countries. EClinical Medicine. 2024;75:102778. https://doi.org/10.1016/j.eclinm.2024.102778Hutchinson B, Husain MJ, Nugent R, Kostova D. Comparing scale up of status quo hypertension care against dual combination therapy as separate pills or single pill combinations: an economic evaluation in 24 low- and middle-income countries. EClinical Medicine. 2024;75:102778. https://doi.org/10.1016/j.eclinm.2024.102778

The authors declare that there are no conflicts of interest present.